EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD147 ‐Conjugated Minocycline Nanomicelles Alleviate Neuroinflammation and Improve Neurological Function Following Intracerebral Hemorrhage

Yang Liu, Yun Chen, Yuanyuan Liu, Zhe Li, Qingli Wang, V Wee Yong iD, Ruixue Wei, Mengzhou Xue iD

CNS Neuroscience & Therapeutics · 2026-08 · 32 (8)

DOI: 10.1002/cns.71069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 20.08.2026. Verfasst von Yang Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Minocycline, Cerebral Hemorrhage, Micelles, Basigin. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Henan Province Key Research and Development and Promotion Program, Health Commission of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intracerebral hemorrhage (ICH) remains one of the most devastating subtypes of stroke, characterized by high mortality and limited therapeutic options. Neuroinflammation is recognized as a critical determinant of secondary brain injury following ICH. Minocycline, a broad‐spectrum tetracycline antibiotic, has been shown to attenuate hematoma expansion, reduce blood–brain barrier (BBB) disruption, and improve neurological outcomes in preclinical ICH models. However, its clinical translation has been limited by poor aqueous solubility, low bioavailability, and dose‐related systemic toxicity.

Methods

We designed a brain‐targeted nanotherapeutic system based on minocycline‐loaded polymeric nanomicelles conjugated with anti‐CD147 monoclonal antibodies (MINO@PNM@CD147). The nanomicelles were synthesized using a co‐solvent evaporation method, followed by covalent conjugation of CD147 antibodies via amide bond formation. The physicochemical properties, biocompatibility, and targeting efficiency of the formulation were characterized in vitro. Therapeutic efficacy was evaluated in a collagenase‐induced ICH mouse model using histopathological, biochemical, and behavioral assessments.

Results

MINO@PNM@CD147 exhibited a uniform spherical morphology with an average hydrodynamic diameter of 13.5 nm and high colloidal stability. In vitro studies demonstrated excellent cellular compatibility and effective suppression of pro‐inflammatory mediators in lipopolysaccharide (LPS)‐activated BV‐2 cells. In vivo fluorescence imaging confirmed targeted accumulation of MINO@PNM@CD147 in perihematomal regions. Treatment markedly reduced neuronal degeneration, microglia and astrocyte activation, leukocyte infiltration, and cell apoptosis, while significantly attenuating the release of inflammatory mediators. Moreover, MINO@PNM@CD147 administration led to substantial improvements in neurological function compared with free minocycline or non‐targeted formulations.

Conclusion

Our findings highlight that MINO@PNM@CD147 combines anti‐inflammatory efficacy with precise brain‐targeted delivery, thereby offering a potent and safe nanotherapeutic strategy for mitigating neuroinflammation and promoting recovery after ICH. This work provides a promising translational platform for nanomedicine‐based interventions in ICH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MinocyclineCerebral HemorrhageMicellesBasiginNeuroinflammatory DiseasesAnimalsMiceMaleMice, Inbred C57BLNanoparticlesHumans

Stichwörter der Autor:innen

anti‐CD147 antibodybrain targetingintracerebral hemorrhageminocyclinenanomicellesneuroinflammationneuroprotection

Substanzen

MinocyclineMicellesBasigin

Autor:innen und Institutionen

  • Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Henan International Joint Laboratory of Intracerebral Hemorrhage and Brain Injury, Zhengzhou University, Zhengzhou, Henan, China.
  • Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: V Wee Yong, Mengzhou Xue

Förderung

  • National Natural Science Foundation of China
  • Henan Province Key Research and Development and Promotion Program
  • Health Commission of Henan Province

Zitieren

APA

Liu, Y., Chen, Y., Liu, Y., Li, Z., Wang, Q., Yong, V. W., Wei, R., & Xue, M. (2026). CD147 ‐Conjugated Minocycline Nanomicelles Alleviate Neuroinflammation and Improve Neurological Function Following Intracerebral Hemorrhage. CNS Neuroscience & Therapeutics, 32(8). https://doi.org/10.1002/cns.71069

Vancouver

Liu Y, Chen Y, Liu Y, Li Z, Wang Q, Yong VW, et al. CD147 ‐Conjugated Minocycline Nanomicelles Alleviate Neuroinflammation and Improve Neurological Function Following Intracerebral Hemorrhage. CNS Neuroscience & Therapeutics. 2026;32(8). doi:10.1002/cns.71069

BibTeX
@article{Liu2026,
  author = {Liu, Yang and Chen, Yun and Liu, Yuanyuan and Li, Zhe and Wang, Qingli and Yong, V Wee and Wei, Ruixue and Xue, Mengzhou},
  title = {CD147 ‐Conjugated Minocycline Nanomicelles Alleviate Neuroinflammation and Improve Neurological Function Following Intracerebral Hemorrhage},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {8},
  doi = {10.1002/cns.71069}
}
Kostenlos starten →